A5057983232- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Cancer Treatment and Pharmacology
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Amyloidosis: Diagnosis, Treatment, Outcomes
- vaccines and immunoinformatics approaches
- Neutropenia and Cancer Infections
- T-cell and B-cell Immunology
- COVID-19 and healthcare impacts
- COVID-19 Clinical Research Studies
- Blood disorders and treatments
- Glycosylation and Glycoproteins Research
- Cholinesterase and Neurodegenerative Diseases
- Cancer therapeutics and mechanisms
St Vincent's Hospital Sydney
2025
UNSW Sydney
2025
Memorial Sloan Kettering Cancer Center
2015-2024
Cornell University
2015-2024
University of Miami
2024
Kettering University
2012-2023
Massachusetts General Hospital
2023
Hadassah Medical Center
2023
City of Hope
2023
Sylvester Comprehensive Cancer Center
2023
Multiple myeloma is the most common indication for high-dose chemotherapy and autologous stem cell transplantation (ASCT), lenalidomide maintenance after transplant now standard. Although doubles progression-free survival, almost all patients eventually relapse. Posttransplant immunotherapy to improve outcomes ASCT therefore has great merit but first requires delineation of dynamics immune reconstitution. We evaluated lymphocyte composition function guide optimal timing identify potential...
Recently, the benefit of adding daratumumab to proteasome inhibitor-based, 3-drug combination bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma who underwent high-dose melphalan chemotherapy autologous hemopoietic cell transplant was assessed. Here, we examine addition second-generation carfilzomib, dexamethasone.To assess safety effectiveness carfilzomib-lenalidomide-dexamethasone-daratumumab therapy myeloma, in absence transplant.Clinical...
Immune recovery post–cellular therapies is an important predictor of response to the anti–SARS-CoV-2 vaccine and can be used guide timing primary vaccination, as well booster vaccine, after therapy.
Abstract B-cell maturation antigen (BCMA)–targeting therapeutics have dramatically improved outcomes in relapsed/refractory multiple myeloma (RRMM). However, whether the mechanisms of resistance between these therapies are shared and how identification such before therapy initiation could refine clinical decision-making remains undefined. We analyzed for 72 RRMM patients treated with teclistamab, a CD3 × BCMA bispecific antibody, 42% (30/72) whom had prior BCMA-directed exposure. Malignant...
We aimed to identify whether the use of autologous hematopoietic cell transplantation (HCT) impacts outcomes for multiple myeloma patients with gains chromosome 1q (+1q). retrospectively identified 95 patients, 21% having +1q. For +1q, overall response rate induction was 85%, 40% ≥ VGPR and 20% achieving a CR, similar non +1q (p = .64). The median PFS from diagnosis 2.1 years (95% CI: 1.2–not reached (NR)) vs 4.3 3.3 yrs–NR) without .003). Median OS 4.4 2.9–NR) not reached, respectively...
Abstract Multiple myeloma (MM) progression is characterized by the seeding of cancer cells in different anatomic sites. To characterize this evolutionary process, we interrogated, whole genome sequencing, 25 samples collected at autopsy from 4 patients with relapsed MM and an additional set 125 exomes 51 patients. Mutational signatures analysis showed how cytotoxic agents introduce hundreds unique mutations each surviving cell, detectable bulk sequencing only cases clonal expansion a single...
Abstract Purpose: Sustained minimal residual disease (MRD) negativity is associated with long-term survival in multiple myeloma. The gut microbiome affected by diet, and turn can modulate host immunity, for example through production of short-chain fatty acids including butyrate. We hypothesized that dietary factors affect the (abundance butyrate-producing bacteria or stool butyrate concentration) may be myeloma outcomes. Experimental Design: examined relationship (via a food frequency...
Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies mechanisms of resistance have yet be fully delineated. We conducted real-world retrospective study commercial teclistamab, capturing both clinical outcomes immune correlates response cohort (n = 52) with advanced R/RMM. Teclistamab was highly overall rate (ORR) 64%,...
Despite being the mainstay of management for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), there is limited data regarding impact tocilizumab (TCZ) corticosteroids (CCS) on chimeric antigen receptor (CAR) T-cell efficacy in multiple myeloma (MM). The present study aims to evaluate prognostic these immunosuppressants recipients BCMA- or GPRC5D-directed CAR T cells relapsed/refractory MM. Our retrospective cohort involved patients treated with...
Abstract B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates (ADC). The primary endpoint was severe (grade ≥3) infection incidence. Amongst 256 patients, 92 received CAR-T, 55 BsAb 109 ADC....
We compared the efficacy of human Langerhans cells (LC) as tumor immunogens in vivo with monocyte-derived dendritic (moDC) and investigated how interleukin 15 (IL15) supports optimal DC-stimulated antitumor immunity.American Joint Committee on Cancer stage III/IV melanoma patients participated this first clinical trial comparing peptide-pulsed LC moDC vaccines (NCT00700167, www.ClinicalTrials.gov). Correlative studies evaluated mechanisms mediating IL15 support immunity.Both DC were safe...
Posttransplant vaccination targeting residual disease is an immunotherapeutic strategy to improve antigen-specific immune responses and prolong disease-free survival after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We conducted a phase 1 vaccine trial determine the safety, toxicity, immunogenicity of Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, Wilms tumor (WT1) messenger RNA (mRNA), ASCT MM. Ten patients received priming immunization...
Abstract Purpose: Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been shown to induce the expansion of circulating multiple myeloma–reactive lymphocytes and consolidation clinical response following autologous hematopoietic transplant (auto-HCT). Patients Methods: In this randomized phase II trial (NCT02728102), we assessed effect DC/MM fusion vaccination, GM-CSF, lenalidomide maintenance as compared control arms GM-CSF or alone on rates induction myeloma–specific...